CEA dynamics for predicting response after anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer.

ABSTRACT: Carcinoembryonic antigen (CEA) is the most widely used tumor marker in metastatic colorectal cancer (mCRC). However, its potential as a predictive marker of progression in mCRC during systemic chemotherapy, particularly in patients receiving monoclonal antibodies as a combination therapy, has remained of interest. Herein, we investigated whether CEA changes could predict disease progression and clinical outcomes in patients with mCRC cotreated with systemic chemotherapy and/or biologic agents. A total of 1261 patients with mCRC undergoing a first-line systemic treatment were included in this retrospective study. We analyzed the optimal cut-off value for CEA changes to predict progression at the first response evaluation by the treatment arm (chemotherapy alone, chemotherapy plus anti-vascu

SUBMITTER: Kang S 

PROVIDER: S-EPMC10130020 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature